Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 12% – Here’s What Happened

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) traded up 12% during mid-day trading on Tuesday . The company traded as high as $42.71 and last traded at $43.8280. 578,700 shares were traded during mid-day trading, a decline of 13% from the average session volume of 662,264 shares. The stock had previously closed at $39.12.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Wednesday, October 8th. HC Wainwright boosted their price target on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the company a “buy” rating in a report on Monday, November 10th. Truist Financial upped their price target on shares of Dianthus Therapeutics from $56.00 to $63.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Finally, Wedbush reiterated an “outperform” rating and set a $46.00 price objective on shares of Dianthus Therapeutics in a report on Monday, December 22nd. Eight research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $64.43.

Dianthus Therapeutics Stock Performance

The company has a market cap of $1.92 billion, a P/E ratio of -12.89 and a beta of 1.55. The firm has a 50 day moving average price of $40.79 and a 200-day moving average price of $32.33.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.11). Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. The company had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.58 million. On average, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Simrat Randhawa sold 109,031 shares of the stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $38.14, for a total transaction of $4,158,442.34. Following the completion of the sale, the executive vice president owned 4,000 shares in the company, valued at $152,560. This represents a 96.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Ryan Savitz sold 20,000 shares of the stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $45.18, for a total value of $903,600.00. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 216,538 shares of company stock valued at $8,283,175. Company insiders own 16.56% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Raymond James Financial Inc. acquired a new stake in shares of Dianthus Therapeutics during the 2nd quarter valued at about $27,000. Parkside Financial Bank & Trust raised its position in Dianthus Therapeutics by 131.7% in the third quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after purchasing an additional 540 shares in the last quarter. Russell Investments Group Ltd. bought a new position in Dianthus Therapeutics during the third quarter worth about $64,000. Tower Research Capital LLC TRC lifted its stake in Dianthus Therapeutics by 330.7% during the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after purchasing an additional 3,317 shares during the period. Finally, AlphaQuest LLC acquired a new stake in Dianthus Therapeutics during the second quarter valued at approximately $94,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.